News Flow Makes Me Want To Buy AstraZeneca plc

I’m thinking of buying AstraZeneca plc (LON: AZN) and here’s why…

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) (NYSE: AZN.US) has had a challenging few years, with its ‘patent cliff’ being a key reason why shares have struggled to make ground.

However, 2013 has been a completely different year for the company, with news flow being positive rather than negative and the company getting on with making a comeback from the previous year’s disappointment.

Indeed, I believe there is yet more encouraging news flow to come, with AstraZeneca continuing to make progress towards its goal of repairing the damage caused by the loss of key ‘blockbuster’ drugs and the lack of suitable replacements.

In turn, I believe that it is only a matter of time before the market realises that AstraZeneca is in a very different situation to where it was at the start of 2013 and that, moreover, it is turning itself around and sowing the seeds for future growth.

However, strong news flow is not the only reason why I’m keen to buy more shares in AstraZeneca.

Indeed, although the company is in the process of losing the exclusivity it had on many of its patented blockbuster drugs, it not only continues to have an attractive portfolio of patented drugs, but is also acquiring companies that themselves enjoy relatively high barriers to entry.

So, although entry barriers are perhaps not quite as high as they once were, AstraZeneca remains a very difficult company to compete against. Furthermore, as it continues to make acquisitions in niche areas it will develop further specialisms and capabilities, thereby increasing entry barriers still further. In turn, this should mean that margin growth once again appears on the horizon.

In addition, I believe that shares currently offer good value when looked at using the price-to-earnings (P/E) ratio. AstraZeneca currently trades on a P/E of 10 using 2013 earnings per share, while the FTSE 100 and wider healthcare industry group trade on P/Es of 15 and 16.8 respectively.

So, I believe that AstraZeneca’s news flow should continue to be strong, with it being just a matter of time before the market decides that shares deserve a higher rating. Furthermore, a relatively low P/E and barriers to entry mean that I want to add to my position in the company.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Peter owns shares in AstraZeneca.

More on Investing Articles

Investing Articles

Here’s the growth forecast for Nvidia shares through to 2026!

Demand for Nvidia shares has soared as investors eye up US growth stocks. Royston Wild looks at the chipmaker's earnings…

Read more »

a couple embrace in front of their new home
Investing Articles

Down 30% in 3 months, is the Taylor Wimpey share price too cheap for me to ignore?

Taylor Wimpey’s share price has plummeted since September and the stock now yields 8%. Should our writer buy the shares…

Read more »

Investing Articles

Is the S&P 500 heading for a correction in 2025?

This writer wonders whether the blue-chip US index is ready for a stumble, with one popular S&P 500 share up…

Read more »

Investing Articles

£15,000 invested in Tesco shares at the start of 2024 is now worth…

This writer takes a look at the performance of Tesco shares since the start of last year and considers whether…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

3 passive income ideas for Stocks & Shares ISA investors to consider!

Searching for ways to make a gigantic second income? Royston Wild reveals three ways that ISA investors could build long-term…

Read more »

Investing Articles

Beaten-down FTSE 250: a chance to get rich in 2025?

FTSE 250 stocks have endured a tough few years, with these typically UK-focused businesses suffering amid broad macroeconomic challenges.

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

6.5% dividend yield! Here’s the dividend forecast for BP shares through to 2026

City analysts expect the dividend on BP shares to keep growing. But just how robust are current estimates? Royston Wild…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Dividend Shares

Avoid these 2 mistakes that investors make with dividend stocks

Our writer examines the various pitfalls that new investors typically face when considering dividend stocks for passive income. 

Read more »